These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Reversibility of lipid deposition. Wolfram G Nutr Metab; 1973; 15(1):141-3. PubMed ID: 4711716 [No Abstract] [Full Text] [Related]
46. [Clinico-experimental studies of the influence of Atherolip on lipid and carbohydrate metabolism]. Hammerl H; Kränzl C; Pichler O; Studlar M Med Welt; 1969 Aug; 31():1715-7. PubMed ID: 4895455 [No Abstract] [Full Text] [Related]
47. Treatment of hyperlipidemia with the ethyl-ester of chlorophenoxyisobutyrate and androsterone. Schatz IJ Henry Ford Hosp Med J; 1965 Dec; 13(4):447-56. PubMed ID: 5325188 [No Abstract] [Full Text] [Related]
48. [Treatment of dyslipemias with the association of dx-thyroxine and choleretics]. Martinelli M; Albini U; Villecco A Boll Soc Ital Cardiol; 1970; 15(6):539-43. PubMed ID: 5517650 [No Abstract] [Full Text] [Related]
49. [Classification and treatment of hyperlipidemia: normolipemic treatments in 1972]. Cloarec M Therapeutique; 1972 Dec; 48(10):653-6. PubMed ID: 4661289 [No Abstract] [Full Text] [Related]
50. [Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)]. Koschinsky T; Lenhard P; Gries FA; Vogelberg KH; Wolfram G; Lang PD; Vollmar J Med Klin; 1977 Sep; 72(38):1537-43. PubMed ID: 904549 [TBL] [Abstract][Full Text] [Related]
51. Reduction of serum cholesterol and triglyceride levels by the combined administration of neomycin and clofibrate. Samuel P; Holtzman CM; Meilman E; Sekowski I Circulation; 1970 Jan; 41(1):109-14. PubMed ID: 5420622 [No Abstract] [Full Text] [Related]
52. [The effect of ethyl-chlorophenoxyisobutyrate on the serum lipids in coronary sclerosis]. Keller L; Rétsági G; Sebestyén M; Diczendy S; Erdélyi G Z Gesamte Inn Med; 1966 Mar; 21(6):169-72. PubMed ID: 5988081 [No Abstract] [Full Text] [Related]
53. Atromid-S for the reduction of plasma lipids. Med Lett Drugs Ther; 1967 Jun; 9(12):45-7. PubMed ID: 6037633 [No Abstract] [Full Text] [Related]
54. [Treatment of hypercholesterinemia with beta-pyridylcarbinol. II. Side effects and disscussion]. Zöllner N; Gudenzi M Med Klin; 1966 Dec; 61(51):2036-40. PubMed ID: 5996572 [No Abstract] [Full Text] [Related]
55. [Therapy of primary hyperlipemia]. Schneider J; Kaffarnik H Dtsch Med Wochenschr; 1971 May; 96(19):831-2. PubMed ID: 5574353 [No Abstract] [Full Text] [Related]
56. Blood lipids and lipoproteins in atherogenesis. Brown DF Am J Med; 1969 May; 46(5):691-704. PubMed ID: 4892338 [No Abstract] [Full Text] [Related]
57. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Dunnigan MG; Cochrane MA; Kelly A; Scott JW Q J Med; 1974 Jan; 43(169):33-48. PubMed ID: 4362786 [No Abstract] [Full Text] [Related]
58. MULTICENTRE TRIAL IN THE UNITED KINGDOM AND IRELAND OF A MIXTURE OF ETHYL CHLOROPHENOXYISOBUTYRATE AND ANDROSTERONE (ATROMID). A PRELIMINARY REPORT. GREEN KG; INMAN WH; THORP JM J Atheroscler Res; 1963; 3():593-616. PubMed ID: 14104298 [No Abstract] [Full Text] [Related]
59. [Effect of ethyl alpha-p-chlorophenoxyisobutyrate (Clofibrate) on lipids, cholesterol and uric acid in diabetes mellitus]. Orsetti A; Mirouze J Therapie; 1966; 21(3):685-91. PubMed ID: 5942133 [No Abstract] [Full Text] [Related]